

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-479US1	Application No. 10/558,354
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Boughton-Smith	
		Filing Date August 24, 2006	Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	3,464,998	09/02/1969	Krimmel			
	AB	3,471,491	10/07/1969	Venkatachala et al.			
	AC	4,349,552	09/14/1982	Takaya et al.			
	AD	4,751,292	06/14/1988	Fox			
	AE	5,399,564	03/21/1995	Hackler et al.			
	AF	5,804,588	09/08/1998	Dyke et al.			
	AG	6,201,024	03/13/2001	Baxter et al.			
	AH	6,242,470	06/05/2001	Baxter et al.			
	AI	6,303,659	10/16/2001	Baxter et al.			
	AJ	6,492,355	12/10/2002	Alcaraz et al.			
	AK	6,720,452	04/13/2004	Alcaraz et al.			
	AL	6,881,754	04/19/2005	Alcaraz et al.			
	AM	6,908,939	06/21/2005	Bernardon et al.			
	AN	6,927,219	08/09/2005	Duplantter et al.			
	AO	6,949,539	09/27/2005	Alcaraz et al.			
	AP	7,129,246	10/31/2006	Alcaraz et al.			
	AQ	7,227,038	06/05/2007	Caffrey et al.			
	AR	2004-0236109	11/25/2004	Van Straten et al.			
	AS	2005-0090524	04/28/2005	Ford et al.			
	AT	2006-0247257	11/02/2006	Dixon			
	AU	2007-0010497	01/11/2007	Boughton-Smith			
	AV	2007-0281931	12/06/2007	Boughton-Smith			
	AW	2007-0037830	02/15/2007	Cladingboel et al.			
	AX	2007-0082930	04/12/2007	Boughton-Smith et al.			

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or	Class	Subclass	Translation
Examiner Signature				Date Considered			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-479US1	Application No. 10/558,354
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Boughton-Smith	
		Filing Date August 24, 2006	Group Art Unit

							Yes	No
	AY	BE 650919 A	07/23/1964	Belgium			English Abstract only	
	AZ	DE 1943404 A	12/17/1970	Germany			English Abstract only	
	AAA	EP 0002065	05/30/1979	Europe				
	ABB	EP 0501656 B1	09/02/1992	Europe				
	ACC	EP 0867436	09/30/1998	Europe			English Abstract only	
	ADD	EP 0940391 B1	09/08/1999	Europe				
	AEE	EP 1310493	05/14/2003	Europe				
	AFF	WO 90/10622	09/20/1990	WIPO			English Abstract	
	AGG	WO 95/04720	02/16/1995	WIPO				
	AHH	WO 97/19926	06/05/1997	WIPO				
	AII	WO 99/26927	06/03/1999	WIPO				
	AJJ	WO 99/29660	06/17/1999	WIPO				
	AKK	WO 99/29661	06/17/1999	WIPO				
	ALL	WO 99/18074	04/15/1999	WIPO				
	AMM	WO 00/61569	10/19/2000	WIPO				
	ANN	WO 00/73283	12/07/2000	WIPO				
	AOO	WO 00/75120	12/14/2000	WIPO				
	APP	WO 01/42194	06/14/2001	WIPO				
	AQQ	WO 01/44170	06/21/2001	WIPO				
	ARR	WO 01/94338	12/13/2001	WIPO				
	ASS	WO 02/096426	12/05/2002	WIPO				
	ATT	WO 03/041707	05/22/2003	WIPO				
	AUU	WO 03/042190	05/22/2003	WIPO				
	AVV	WO 03/042191	05/22/2003	WIPO				
	AWW	WO 03/080579	10/02/2003	WIPO				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-479US1	Application No. 10/558,354
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Boughton-Smith	
		Filing Date August 24, 2006	Group Art Unit

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AXX	WO 2004/058270	07/15/2004	WIPO				
	AYY	WO 2004/106305	12/09/2004	WIPO				
	AZZ	WO 2005/009968	02/03/2005	WIPO				
	AAAA	WO 2006/025783	03/09/2006	WIPO				
	ABBB	WO 2006/059945	06/08/2006	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	ACCC	Accession No. 2003:42109, CAS Registry No. 487064-48-2
	ADDD	Alcaraz et al., "Preparation of Adamantane Derivatives as P2X7 Receptor Antagonists, CAS Accession No. 2001:904155
	AEEE	Alcaraz et al., "Novel P2X7 Receptor Antagonists" <i>Bioorganic and Medicinal Chemistry Letters</i> , 13:4043-4046 (2003)
	AFFF	Baxter et al., "Hit-to-Lead Studies: The Discovery of Potent Adamantane Amide P2X7 Receptor Antagonists," <i>Bioorganic and Medicinal Chemistry Letters</i> , 13:4047-4050 (2003)
	AGGG	Bourrie et al., "SSR125329A, A High Affinity Receptor Ligand with Potent Anti-Inflammatory Properties," <i>Eur. J. of Pharm.</i> , 456:123-131 (2002)
	AHHH	Costakis et al., "Synthesis of Some Adamantane Derivatives of 2-Aminobenzothiazoles", <i>Journal of Medicinal Chemistry</i> 14(12):1222-1223 (1971)
	AIII	Dell'Antonio et al., "Antinociceptive effect of a new P _{2Z} /P2X7 antagonist, oxidized ATP, in arthritic rats", <i>Neuroscience Letters</i> 327:87-90 (2002)
	AJJJ	Di Virgilio et al., "Purinergic P2X ₇ -Receptor: A Pivotal Role in Inflammation and Immunomodulation", <i>Drug Development Research</i> 45:207-213 (1998)
	AKKK	Ferrari et al., "Extracellular ATP Triggers IL-1 β Release by Activating the Purinergic P2Z Receptor of Human Macrophages", <i>J. Immunol.</i> 159:1451-1458 (1997)
	ALLL	Ferrari et al., "Purinergic Modulation of Interleukin-1 β Release from Microglial Cells Stimulated with Bacterial Endotoxin", <i>J. Exp. Med.</i> 185(3):579-582 (1997)
	AMMM	Goldman et al., "Valdecoxib. A COX-2 inhibitor for treatment of osteoarthritis, rheumatoid arthritis, and primary dysmenorrheal", <i>Formulary</i> 37:68-77 (2002)
	ANNN	Haagsma et al., "Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled double-blind, 52 week clinical trial", <i>Br J Rheumatol</i> 36:1082-1088 (1997)
	AOOO	Henderson et al., "Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist", <i>Cytokine</i> 3(3):246-249 (1991)
	APPP	Ho et al., "Synthesis of a Peptidomimetic Tricyclic Tetrahydrobenzo[<i>ij</i>] quinoline as a VLA-4 Antagonist", <i>J. Org. Chem.</i> 65:6743-6748, page 6745, scheme 5, (27) (2000)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-479US1	Application No. 10/558,354
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Boughton-Smith	
		Filing Date August 24, 2006	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AQQQ	Humphreys et al., "Modulation of P2X ₇ nucleotide receptor expression by pro-and anti-inflammatory stimuli in THP-1 monocytes", <i>Journal of Leukocyte Biology</i> 64:265-273 (1998)
	ARRR	Kadota et al., "Significance of IL-1 β and IL-1 receptor antagonist (IL-1Ra) in bronchoalveolar lavage fluid (BALF) in patients with diffuse panbronchiolitis (DPB)", <i>Clin Exp. Immunol.</i> 103:461-466 (1996)
	ASSS	Khurana et al., "Clinical aspects of rheumatoid arthritis", <i>Pathophysiology</i> , Volume 12, Issue 3, Abstract (2005)
	ATTT	Kirkham, "Interleukin-1, Immune Activation Pathways, and Different Mechanisms in Osteoarthritis and Rheumatoid Arthritis", <i>Annals of the Rheumatic Diseases</i> , 50:395-400 (1991)
	AUUU	Li et al., "Should atherosclerosis be considered a cancer of the vascular wall?" <i>Medical Hypotheses</i> , 64:694-698 (2005)
	AVVV	Mackenzie et al., "Could rheumatoid arthritis have an infectious aetiology?" <i>Drug Discovery Today: Disease Mechanism</i> , Volume 2, Issue 3, Abstract (2005)
	AWWW	Maini et al., "Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial", <i>The Lancet</i> 354:1932-1939 (1999)
	AXXX	Modena et al., "Plant Growth Regulating Activities of 2-[2-(Arylamino)-2-oxoethyl]benzoic acids", <i>Il Farmaco</i> 48(4):567-572 (1993)
	AYYY	Otterness et al., "Possible Role of IL-1 in Arthritis: Effects of Prostaglandins in the Regulation of IL-1 Synthesis and Actions", <i>Agent Act</i> 39 (Suppl):109-120 (1993)
	AZZZ	Rains et al., "Sulfasalazine. A review of its Pharmacological Properties and Therapeutic Efficacy in the Treatment of Rheumatoid Arthritis", <i>Drugs</i> 50:137-156 (1995)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	